Author: Daniel B Larremore; Bailey K Fosdick; Kate M Bubar; Sam Zhang; Stephen M Kissler; C. Jessica E. Metcalf; Caroline Buckee; Yonatan Grad
Title: Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys Document date: 2020_4_20
ID: c4cs14ja_3
Snippet: Serological testing is a critical component of the response to COVID-19 as well as to future epidemics. Assessment of population seropositivity, a measure of the prevalence of individuals who have been infected in the past and developed antibodies to the virus, can address gaps in knowledge of the cumulative disease incidence. This is particularly important given inadequate viral diagnostic testing and incomplete understanding of the rates of mil.....
Document: Serological testing is a critical component of the response to COVID-19 as well as to future epidemics. Assessment of population seropositivity, a measure of the prevalence of individuals who have been infected in the past and developed antibodies to the virus, can address gaps in knowledge of the cumulative disease incidence. This is particularly important given inadequate viral diagnostic testing and incomplete understanding of the rates of mild and asymptomatic infections (1) . In this context, serological surveillance has the potential to provide information about the true number of infections, allowing for robust estimates of case and infection fatality rates and for the parameterization of epidemiological models to evaluate the possible impacts of specific interventions and thus guide public health decision-making.
Search related documents:
Co phrase search for related documents- asymptomatic mild infection and cumulative disease incidence: 1
- asymptomatic mild infection and decision making: 1
- asymptomatic mild infection and diagnostic testing: 1
- asymptomatic mild infection and disease incidence: 1
- case infection fatality rate and epidemiological model: 1
- critical component and decision making: 1, 2, 3, 4, 5, 6, 7
- critical component and diagnostic testing: 1, 2, 3
- cumulative disease incidence and decision making: 1
- cumulative disease incidence and disease incidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cumulative disease incidence and epidemiological model: 1, 2
- cumulative disease incidence and future epidemic: 1, 2
- decision making and develop past: 1
- decision making and diagnostic testing: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- decision making and disease incidence: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- decision making and epidemiological model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- decision making and future epidemic: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- decision making and gap address: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- decision making and incomplete understanding: 1, 2, 3, 4, 5, 6, 7
- diagnostic testing and gap address: 1, 2
Co phrase search for related documents, hyperlinks ordered by date